The development and characterization of SDF1α-elastin-like-peptide nanoparticles for wound healing.
Chronic skin wounds are characterized by poor re-epithelialization, angiogenesis and granulation. Previous work has demonstrated that topical stromal cell-derived growth factor-1 (SDF1) promotes neovascularization, resulting in faster re-epithelialization of skin wounds in diabetic mice. However, the clinical usefulness of such bioactive peptides is limited because they are rapidly degraded in the wound environment due to high levels of proteases. Here, we describe the development of a recombinant fusion protein comprised of SDF1 and an elastin-like peptide that confers the ability to self-assemble into nanoparticles. The fusion protein and recombinant human SDF1 showed similar binding characteristics, as indicated by the measured equilibrium dissociation constant (Kd) for the binding of free SDF1 or the fusion protein to the CXCR4 receptor. The biological activity of SDF1-ELP, as measured by intracellular calcium release in HL60 cells was dose dependent, and also very similar to that of free SDF1. In contrast, the biological activity of SDF1-ELP in vivo was significantly superior to that of free SDF1. When applied to full thickness skin wounds in diabetic mice, wounds treated with SDF1-ELP nanoparticles were 95% closed by day 21, and fully closed by day 28, while wounds treated with free SDF1, ELP alone, or vehicle were only 80% closed by day 21, and took 42days to fully close. In addition, the SDF1-ELP nanoparticles significantly increased the epidermal and dermal layer of the healed wound, as compared to the other groups. These results indicate that SDF1-ELP fusion protein nanoparticles are promising agents for the treatment of chronic skin wounds.
Department of Chemical and Biochemical Engineering, Rutgers University, 98 Brett Road, Piscataway, NJ 08854, USA.
Agnes
A
Yeboah
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA.
Rick I
RI
Cohen
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA.
Renea
R
Faulknor
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA.
Rene
R
Schloss
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA; Center for Engineering in Medicine, Massachusetts General Hospital and Shriners Burns Hospital, 51 Blossom Street, Boston, MA 02114, USA. Electronic address: yarmush@rci.rutgers.edu.
Martin L
ML
Yarmush
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA. Electronic address: fberthia@rci.rutgers.edu.
Francois
F
Berthiaume
D000818:Animals; D054377:Chemokine CXCL12 / Q000008:administration & dosage* / Q000627:therapeutic use; D003920:Diabetes Mellitus; D004549:Elastin; D018922:HL-60 Cells; D006801:Humans; D008822:Mice, Transgenic; D053758:Nanoparticles / Q000008:administration & dosage* / Q000627:therapeutic use; D010455:Peptides / Q000008:administration & dosage* / Q000627:therapeutic use; D019718:Receptors, CXCR4 / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D012867:Skin / Q000293:injuries*; D014945:Wound Healing / Q000187:drug effects*
D054377:Chemokine CXCL12; D010455:Peptides; D019718:Receptors, CXCR4; D011993:Recombinant Fusion Proteins; D004549:Elastin
Elastin like peptides (ELP); Nanoparticles; Skin; Stromal cell-derived factor-1 (SDF1); Wound healing